Bolt Biotherapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bolt Biotherapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 34% in 3 years; of every extra $100 of sales, $2,783 became extra profit. Higher than almost all Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 95% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 3 of 3. Steadier than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-535.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 95% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$2,783Sales grew 34% in 3 years; of every extra $100 of sales, $2,783 became extra profit.
Higher than almost all Healthcare companies in United States.
Asset Productivity Ratio
+34% / -75%In 3 years sales changed by +34% while total assets changed by -75%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-14.1×Operating cash was negative last year, while some debt falls due within a year.
Higher than 51% of Healthcare companies in United States.
Cash Cushion Ratio
+56%Cash, after subtracting all debt, equals 56% of its market value (net cash).
Higher than 79% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Bolt Biotherapeutics, Inc. made a loss over the last year. Bolt Biotherapeutics, Inc. owes $0.69 for every $1 it owns. Bolt Biotherapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBolt Biotherapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.96The share price is 0.96 times Bolt Biotherapeutics, Inc.'s book value per share, lower than 79% of Healthcare companies in United States.
Market cap
$12 MThe total market value of all of Bolt Biotherapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 86% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$13 MWhat Bolt Biotherapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.56Net worth divided by the number of shares. The share price of $6.27 is 1.0 times this, which is the P/B above.
Return on equity (ROE)
-111.7%Bolt Biotherapeutics, Inc. lost 111.7% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
Owes vs Owns
0.69×Bolt Biotherapeutics, Inc. owes $0.69 for every $1 it owns (moderate), higher than 71% of Healthcare companies in United States.
Dividend yield
NoneBolt Biotherapeutics, Inc. does not currently pay a dividend.
Revenue growth
+0%Revenue rose 0% in the year to Dec 2025, and grew 10% a year on average over 3 years.
Profit growth
LossBolt Biotherapeutics, Inc. made a loss in each of the last two years.
Profit margin
-433.7%Bolt Biotherapeutics, Inc. lost $434 for every $100 of revenue.
Cash vs debt
Net cashBolt Biotherapeutics, Inc. held $5 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bolt Biotherapeutics, Inc.: $12 M ÷ $13 M (30 Jun 2026) = 1.0.
What is Bolt Biotherapeutics, Inc.'s return on equity?
Bolt Biotherapeutics, Inc. lost 111.7% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
How much does Bolt Biotherapeutics, Inc. owe compared with what it owns?
Bolt Biotherapeutics, Inc. owes $0.69 for every $1 it owns (moderate), higher than 71% of Healthcare companies in United States.
Does Bolt Biotherapeutics, Inc. pay a dividend?
No. Bolt Biotherapeutics, Inc. does not currently pay a dividend.
Is Bolt Biotherapeutics, Inc.'s revenue growing?
Revenue rose 0% in the year to Dec 2025, and grew 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.